Blood collector Vitalant reported on Thursday a critical shortage of blood as supplies have been significantly impacted by the COVID-19 pandemic.
Since early March, shelter-in-place orders have resulted in a loss of 150,000 uncollected blood donations, while the resumption of surgeries and other medical procedures have caused a 25% increase in the need for blood in the past several weeks.
Calling on donors to alleviate the shortage, Vitalant said that all blood types are critically needed right now, with an especially high need for type O, A-negative and B-negative red blood cells. In addition, platelets are always needed by patients for cancer treatments, surgeries and emergencies. Because of a short shelf life of just five days, the supply of platelets must be continually replenished.
Amgen receives EU marketing authorisation for IMDYLLTRA in ES-SCLC
Anixa secures Canadian patent milestone for ovarian cancer vaccine
Rallybio and Avenzo Therapeutics announce merger agreement and USD215m financing
IBA launches Cyclone iKure for industrial-scale Astatine-211 production
Avacta reports encouraging early efficacy signals for AVA6000 in salivary gland cancer at ASCO 2026
Dizal presents positive NSCLC data for DZD6008 and golidocitinib at ASCO 2026
TiumBio presents Phase 2a interim data for Tosposertib plus pembrolizumab at ASCO 2026
ImmVira reports 100% CRR at 9 months in bladder carcinoma in situ with MVR-T3011
CARsgen presents long-term satri-cel follow-up results at 2026 ASCO Annual Meeting
AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer
Whitehawk Therapeutics to present at Jefferies 2026 Global Healthcare Conference
Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines
CellCarta partners with Sonic Healthcare to commercialise companion diagnostics through Lab Network